Stay informed with the latest litigation news. Explore now

IP Verse

Regeneron Pharmaceuticals competitive analysis

Latest publications and patents of Regeneron Pharmaceuticals New

Explore the latest publications and patents granted to Regeneron Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Sep 9, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Regeneron Pharmaceuticals

EP4605529
Aug 27, 2025Compositions And Methods Comprising Programmable Snrnas For Rna EditingPending
EP4324851
Aug 27, 2025Chimeric Antigen Receptors With Bcma Specificity And Uses ThereofGranted And Under Opposition
EP3538539
Aug 27, 2025Steroids And Protein-Conjugates ThereofGranted And Under Opposition
EP4603120
Aug 20, 2025Devices And Methods For Precision Dose DeliveryPending
EP4601748
Aug 20, 2025Methods For Reducing Alloantibody Levels In Subjects In Need Of Solid Organ TransplantationPending
EP4317456
Aug 20, 2025Piezo Type Mechanosensitive Ion Channel Component 1 (Piezo1) Variants And Uses ThereofGranted
EP4238095
Aug 20, 2025Methods And Systems For Biotherapeutic DevelopmentGranted
EP4098247
Aug 20, 2025Stabilized Formulations Containing Anti-Interleukin-6 Receptor (Il-6R) AntibodiesGranted
EP3957752
Aug 20, 2025Treatment And Inhibition Of Inflammatory Lung Diseases In Patients Having Risk Alleles In The Genes Encoding Il33 And Il1Rl1Granted
EP4596688
Aug 6, 2025Non-Human Animals Having An Engineered Immunoglobulin Lambda Light Chain And Uses ThereofPending

Latest oppositions filed by Regeneron Pharmaceuticals

Explore patent oppositions filed by Regeneron Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 11, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3411476
Enhanced Production Of ImmunoglobulinsTRIANNIJan 24, 2025
EP3819007
Dosing Regimen For Anti-Bcma AgentsAMGENAug 2, 2024
EP4058148
Dosing Regimen For Anti-Bcma AgentsAMGENAug 2, 2024
EP3631454
Treatment Of Lag-3 Positive TumorsBRISTOL MYERS SQUIBBJun 13, 2024
EP3911354
Aav-Mediated Gene Therapy Restoring The Otoferlin GeneCENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRSApr 16, 2024
EP3666797
Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)AMGENFeb 19, 2024
EP3597216
Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses ThereofE R SQUIBB & SONSMay 23, 2023
EP3476942
Long Germline Dh Genes And Long Hcdr3 AntibodiesTRIANNIOct 25, 2022
EP3785536
Adam6 Knockin MiceTRIANNIOct 25, 2022
EP3241435
Animal Models And Therapeutic MoleculesKYMABFeb 25, 2022

Latest patents of Regeneron Pharmaceuticals opposed by its competitors

Explore Regeneron Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4252857
Sep 25, 2024Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)1
EP3506931
Jul 31, 2024Methods For Preventing Or Treating Allergy By Administering An Il-4R Antagonist4
EP3889181
Apr 24, 2024Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist7
EP3460063
Mar 13, 2024Methods And Compositions For The Targeted Modification Of A Genome1
EP3110848
Feb 14, 2024Methods For Treating Skin Infection By Administering An Il-4R Antagonist5
EP3515465
Feb 7, 2024Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R Inhibitor7
EP3973987
Jan 10, 2024Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist6
EP4011915
Nov 15, 2023Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist6
EP3703818
Nov 1, 2023Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist7
EP2967015
Aug 9, 2023Transgenic Mice Expressing Chimeric Major Histocompatibility Complex (Mhc) Class Ii Molecules1

Latest PTAB cases involving Regeneron Pharmaceuticals New

Discover the latest PTAB cases involving Regeneron Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 15, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Regeneron Pharmaceuticals

IPR2025-01268Jul 14, 2025FRESENIUS KABI SWISSBIOSIMREGENERON PHARMACEUTICALSPending
IPR2025-01269Jul 14, 2025FRESENIUS KABI SWISSBIOSIMREGENERON PHARMACEUTICALSPending
IPR2025-00456Jan 15, 2025CELLTRIONREGENERON PHARMACEUTICALSDiscretionary Denial
IPR2025-00233Dec 2, 2024FORMYCONREGENERON PHARMACEUTICALSInstitution Denied
IPR2025-00176Nov 20, 2024SAMSUNG BIOEPISREGENERON PHARMACEUTICALSInstitution Denied
IPR2024-00298Dec 18, 2023BIOCON BIOLOGICSREGENERON PHARMACEUTICALSTerminated-Adverse Judgment
IPR2024-00260Dec 14, 2023CELLTRIONREGENERON PHARMACEUTICALSTerminated-Adverse Judgment
IPR2024-00201Nov 20, 2023BIOCON BIOLOGICSREGENERON PHARMACEUTICALSTerminated-Adverse Judgment
IPR2023-01312Aug 18, 2023SAMSUNG BIOEPISREGENERON PHARMACEUTICALSTerminated-Adverse Judgment
IPR2023-00884Apr 27, 2023SAMSUNG BIOEPISREGENERON PHARMACEUTICALSTerminated-Adverse Judgment

Top competitors of Regeneron Pharmaceuticals

Top competitors of Regeneron Pharmaceuticals based on patent oppositions.